Covaxin can neutralise Delta, Omicron variants of coronavirus: Bharat Biotech
Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay.
New Delhi: Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
In a statement, Bharat Biotech said, “Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants.”
It also mentioned that earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa. The study will be published on the pre-print server, medRXiv, shortly.
COVAXIN( BBV152) booster shown to neutralize both Omicron and Delta variants of SARS-CoV-2: Bharat Biotech pic.twitter.com/LGgqyj9VX5
— ANI (@ANI) January 12, 2022
Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay.
The Hyderabad based company claimed that the neutralization activity of Covaxin boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant and found more than 90 per cent of all individuals boosted with Covaxin showed neutralizing antibodies.
All participants received an initial two-dose schedule of Covaxin on Day 0 and Day 28.
“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, PhD Assistant Professor, Emory Vaccine Center who led the laboratory analysis.
Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations, said the statement.
“We are in a continuous state of innovation and product development for Covaxin. The positive neutralization responses against the Omicron and Delta variants validate our hypothesis of a multi-epitope vaccine generating both humoral and cell-mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covasxin as a universal vaccine for adults and children,” said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.
“The global impact of Omicron shows us that the fight against COVID-19 continues, and we are encouraged that these data demonstrate the value of Covaxin as a primary and booster vaccine. These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations,” said Dr Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc.